SEC Filing Summary: Hemispherx Biopharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Hemispherx Biopharma, Inc. (the "Company") on February 3, 2017, reporting events occurring on February 1, 2017. The filing details the entry into material definitive agreements for a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $1,000,000 from the sale of common stock and warrants.
- Net Proceeds: Estimated at approximately $850,000 after deducting placement agent fees and transaction expenses.
- Securities Issued:
- 1,818,185 shares of Common Stock at $0.55 per share.
- Warrants to purchase 1,363,639 shares of Common Stock.
- Warrant Terms: Initial exercise price of $0.75 per share; exercisable six months after issuance; five-year term.
- Placement Agent Fees: 7% of gross proceeds plus a 1.0% management fee and a $10,000 expense allowance.
Material Changes and Use of Proceeds
The Company entered into Securities Purchase Agreements with certain investors. The net proceeds are designated for:
- Preparation for technology transfer opportunities.
- Expenses related to Ampligen® manufacturing.
- Working capital and general corporate purposes.
The closing of the transaction was expected to occur on or about February 6, 2017, subject to customary closing conditions.
Outlook, Risks, and Unusual Items
The filing includes a Regulation FD disclosure referencing a press release issued on February 2, 2017. The Company notes that the Warrants and shares issuable upon exercise were sold without registration under the Securities Act of 1933, relying on exemptions for transactions not involving a public offering and sales to accredited investors. The filing explicitly states that representations and warranties in the Purchase Agreements are for risk allocation between parties and should not be relied upon as factual characterizations of the Company's condition.
Investor Verification Checklist
- Verify the actual closing date of the transaction (expected February 6, 2017) and confirmation of fund receipt.
- Review the attached Press Release (Exhibit 99.1) for additional management commentary on the capital raise.
- Confirm the dilution impact of the 1,818,185 new shares and 1,363,639 warrant shares on existing shareholders.
- Monitor future filings for updates on the status of Ampligen® manufacturing and technology transfer opportunities funded by this capital.